Watson Pharmaceuticals, Inc and Warner Chilcott Limited announced today that they have entered into Settlement and License Agreements to resolve pending patent litigation related to Warner Chilcott's oral contraceptive products, Loestrin 24 and Femcon Fe. Separately, Warner Chilcott and Watson have entered into a Co-Promotion Agreement relating to Warner Chilcott's Femring product and License and Supply Agreements relating to a Warner Chilcott development-stage oral contraceptive product.
The details can be read here.
No comments:
Post a Comment